Q1 Earnings Forecast for CGEM Issued By William Blair

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings estimates for shares of Cullinan Therapeutics in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.69) per share for the quarter. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. William Blair also issued estimates for Cullinan Therapeutics' Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.79) EPS and FY2028 earnings at ($2.45) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Cullinan Therapeutics in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cullinan Therapeutics has a consensus rating of "Buy" and an average target price of $32.50.

Cullinan Therapeutics Price Performance

Shares of CGEM stock traded up $0.10 during midday trading on Monday, reaching $8.10. 142,457 shares of the company traded hands, compared to its average volume of 459,075. The firm's 50 day simple moving average is $10.45 and its two-hundred day simple moving average is $13.85. The firm has a market cap of $471.59 million, a PE ratio of -2.86 and a beta of -0.16. Cullinan Therapeutics has a 1-year low of $7.90 and a 1-year high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.02.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of hedge funds have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Cullinan Therapeutics by 29.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 91,792 shares of the company's stock valued at $1,118,000 after purchasing an additional 20,881 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Cullinan Therapeutics in the fourth quarter worth about $2,038,000. Two Sigma Advisers LP grew its stake in shares of Cullinan Therapeutics by 22.3% in the fourth quarter. Two Sigma Advisers LP now owns 21,900 shares of the company's stock valued at $267,000 after buying an additional 4,000 shares in the last quarter. Two Sigma Investments LP grew its stake in shares of Cullinan Therapeutics by 83.9% in the fourth quarter. Two Sigma Investments LP now owns 42,205 shares of the company's stock valued at $514,000 after buying an additional 19,261 shares in the last quarter. Finally, Tema Etfs LLC purchased a new stake in shares of Cullinan Therapeutics during the 4th quarter valued at about $346,000. Hedge funds and other institutional investors own 86.31% of the company's stock.

Insiders Place Their Bets

In other news, CEO Nadim Ahmed sold 12,529 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total transaction of $106,872.37. Following the completion of the sale, the chief executive officer now directly owns 430,621 shares of the company's stock, valued at $3,673,197.13. The trade was a 2.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey Alan Jones sold 4,895 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total value of $41,754.35. Following the completion of the transaction, the insider now owns 174,164 shares in the company, valued at approximately $1,485,618.92. This trade represents a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 38,006 shares of company stock valued at $395,604. Company insiders own 6.07% of the company's stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.